Uma visão geral sobre o tratamento da candidíase vulvovaginal recorrente

Abstract

Vulvovaginal candidiasis is a fungal infection of the female reproductive system. It can present itself in an uncomplicated form or in a complicated one. The present study seeks to elucidate the complicated form of the entity, that being, recurrent vulvovaginal candidiasis (CVVR). CVVR is defined as the occurrence of three or more episodes of candidiasis within a 12-month interval. Approximately 75% of women will have at least one episode of vulvovaginal candidiasis in their lifetime, which is considered a very high incidence. The diagnosis is based on the clinical manifestations, however, the signs and symptoms are not pathognomonic, which makes it important to carry out additional tests that seek to identify and differentiate the type of yeast located in the vaginal system. In order to carry out the present study it was applied a methodology based on the selection of articles published in the past five years that were focused on CVVR, the databases utilized were Pubmed and Scielo, the articles considered most relevant to the study were selected and analyzed. It was evidenced that the first line of treatment often instituted for both CVV and CVVR are the azole antifungals. Also, it was demonstred that for increased chances of a successful treatment of CVVR caused by Candida albicans, a suppression regimen, with a prolonged dose of antifungal, is necessary to first promote clinical remission and, after, to establish a maintenance regimen.